Skip to main content

Groundbreaking Study Reinforces Need for Increased Choline Supplementation During Pregnancy

New research from Cornell University finds that doubling recommended prenatal choline significantly improved childhood brain performance

NEW HAMPTON, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — In a new paper1 just published in The FASEB Journal, Cornell University researchers confirmed the critical role choline plays in infant cognitive development. This groundbreaking new research shows that pregnant women who took more than twice the recommended dose of choline during pregnancy had children that demonstrated significant cognitive benefits through early childhood. The original Cornell findings published in 20182 established that higher doses of choline during pregnancy led to improved cognitive performance in infant offspring.

This new paper now highlights that cognitive improvements were both significant and enduring in those same children at the age of seven. VitaCholine® from Balchem was the choline source used in the original 2018 study at Cornell University.

According to the Cornell researchers, even after seven years and without additional choline supplementation, the children born from the higher choline dosage (930 mg) pregnancies maintained their significant cognitive performance advantage over the children from the lower choline dose (480 mg) group. Further, their cognitive performance significantly improved compared to the lower choline dose group as the testing regimen prolonged and the difficulty progressed. This is the first human clinical study to confirm years of previous animal research that the brain-boosting benefits of supplemental choline during pregnancy endure at least into early childhood.

This landmark research may well have an important impact on public health policy according to Shitij Chabba, Vice President of Minerals & Nutrients and Human Nutrition & Health Marketing at Balchem. “Higher maternal intakes of VitaCholine significantly improved children’s ability to stay focused and on-task, even during long, challenging assignments. The cognitive boost from VitaCholine observed in infants continues at least to school age when children begin to tax their brains in educational settings,” said Chabba.

Surprisingly, nine out of ten pregnant women don’t even get the recommended Dietary Reference Intake (DRI) of choline3. They likely need to consume higher amounts of choline for their children to realize these newly discovered heightened cognitive benefits. Many prenatal vitamin manufacturers are beginning to reformulate with higher levels of choline and these study findings are likely to help drive that trend.

“The importance of choline during pregnancy cannot be overstated and this new paper helps establish choline as the premier brain nutrient. The American Medical Association recommends choline inclusion in prenatal vitamins because of the growing body of research that proves its benefits throughout life.” Chabba continued. “This is exciting news for moms – by supplementing with VitaCholine, they give their children the best start in life for enduring, high cognitive performance.”

Cited Sources:

1Bahnfleth, CL, Strupp, BJ, Caudill, MA, Canfield, RL. (2021), Prenatal choline supplementation improves child sustained attention: A 7-year follow-up of a randomized controlled feeding trial. FASEB J. 2022; 36:e22054. https://doi.org/10.1096/fj.202101217R

2Caudill, M.A., Strupp, B.J., Muscalu, L., Nevins, J.E.H. and Canfield, R.L. (2018), Maternal choline supplementation during the third trimester of pregnancy improves infant information processing speed: a randomized, double-blind, controlled feeding study. The FASEB Journal, 32: 2172-2180. https://doi.org/10.1096/fj.201700692RR

3Wallace, T. C., & Fulgoni, V. L. (2017). Usual Choline Intakes Are Associated with Egg and Protein Food Consumption in the United States. Nutrients, 9(8), 839. https://doi.org/10.3390/nu9080839

About Balchem

Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products.

The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals and chelated minerals to the micronutrient agricultural market.

Media contact:

Tracy Snider
tsnider@balchem.com
314-704-0553

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.